BIRMINGHAM, Alabama, July 29 -- The University of Alabama issued the following news:

* * *

Startup advances novel oral Type 1 diabetes therapy to next phase of human testing

*

Anath Shalev, M.D., co-founder of TIXiMEDThe University of Alabama at Birmingham startup TIXiMED Inc. has launched the next phase of clinical testing for a novel oral therapy for Type 1 diabetes, moving the treatment one step closer to potential use in patients.

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:

What's your Affiliation

Government Newspaper / Media Business Public Policy Individual / Student Educators

Email:

Phone:

Organization, if any:

State/Country you are in:

Additional questions or comments:

Submit Form Click here for more information about our products